• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Rational Development of Neuraminidase Inhibitor as Novel Anti-Flu Drug

tetano

Editor, Senior Moderator
Mini Rev Med Chem. 2012 Apr 17. [Epub ahead of print]
Rational Development of Neuraminidase Inhibitor as Novel Anti-Flu Drug.
Chintakrindi A, D'souza C, Kanyalkar M.
Source

Plot 23, Jote Joy Building, Rambhau Salgaonkar Marg, Cuffe Parade, Mumbai 400005, India. meenatul@gmail.com.
Abstract

The highly pathogenic influenza virus has caused many human fatalities and poses an increasing pandemic threat. Neuraminidase inhibitors such as oseltamivir and zanamivir have been widely used in the treatment and have gained remarkable success. Although, they are effective in prevention of influenza; the concern for drug resistance still remains a question. Recently, the availability of crystal structures of the enzyme gave a new trend to the structure based drug designing of neuraminidase inhibitors. The article reviews a detailed understanding of the structural features within neuraminidase enzyme which turnouts to be crucial for future drug development. In depth analysis for the newly proposed spots within the 150 and 430-loop regions in N1 makes it distinguishable among the subtypes. Further we have discussed the various computational studies carried out in optimizing the designing of neuraminidase inhibitors thereby providing new clues to modify the currently available drugs.

PMID:
22512586
[PubMed - as supplied by publisher]

http://www.ncbi.nlm.nih.gov/pubmed/22512586
 
Back
Top Bottom